Drug intelligence / Profile preview

Ligilactobacillus salivarius LS97

Development stage: Preclinical
Lead developer: Wecare Probiotics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Ligilactobacillus salivarius LS97 is a probiotic bacterial strain being investigated for its potential to enhance gastrointestinal and immunological health. Formerly classified as *Lactobacillus salivarius*, this strain is being evaluated in clinical trials as a food supplement to improve intestinal function and immune response in healthy adults. Developed by Inner Mongolia Yili Industrial Group, LS97 is intended to modulate the gut microbiota and interact with the host's mucosal immune system to support overall wellness and maintain gastrointestinal homeostasis.

Other names: Lactobacillus salivarius LS97

Beyond the preview

Go deeper on Ligilactobacillus salivarius LS97.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ligilactobacillus salivarius LS97.

Explore the full profile